Celltrion Past Earnings Performance

Past criteria checks 2/6

Celltrion has been growing earnings at an average annual rate of 1.6%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been growing at an average rate of 14.5% per year. Celltrion's return on equity is 1.1%, and it has net margins of 6.5%.

Key information

1.6%

Earnings growth rate

0.4%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate14.5%
Return on equity1.1%
Net Margin6.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Nov 22
Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Mar 25
Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Recent updates

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Nov 22
Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

Jun 26
Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

May 22
Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

Celltrion, Inc. (KRX:068270) Not Flying Under The Radar

Apr 30
Celltrion, Inc. (KRX:068270) Not Flying Under The Radar

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Mar 25
Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Mar 19
We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

May 05
Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Mar 25
Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Mar 15
Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Feb 24
Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Feb 03
Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 13
Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Dec 23
Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Dec 02
Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Revenue & Expenses Breakdown

How Celltrion makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSE:A068270 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,876,253187,097762,997161,112
30 Jun 242,666,611323,331610,011161,112
31 Mar 242,315,848392,826407,846161,112
31 Dec 232,176,432535,648198,356161,112
30 Sep 232,304,473603,795196,472139,714
30 Jun 232,277,818542,616179,966139,714
31 Mar 232,350,070582,780183,631139,714
31 Dec 222,283,967526,616204,971139,714
30 Sep 222,376,733566,168220,603125,769
30 Jun 222,133,015543,369217,022125,769
31 Mar 221,967,894482,930194,374125,769
31 Dec 211,893,401569,488180,730125,769
30 Sep 211,788,695564,777175,444171,437
30 Jun 211,935,547597,615167,273171,437
31 Mar 211,933,237608,477150,937171,437
31 Dec 201,849,116517,760126,626171,437
30 Sep 201,733,144512,182148,229113,568
30 Jun 201,473,428402,929140,896113,568
31 Mar 201,279,603342,041141,114113,568
31 Dec 191,128,460301,030131,592113,568
30 Sep 19988,284230,443144,915108,060
30 Jun 19930,333225,180131,754108,060
31 Mar 19958,797228,480126,670108,060
31 Dec 18982,075245,755113,897108,060
30 Sep 181,013,790308,254132,37579,660
30 Jun 181,014,774355,009131,87479,660
31 Mar 18997,483381,655125,61279,660
31 Dec 17949,080368,222112,70179,660
30 Sep 17883,631308,46194,72787,856
30 Jun 17819,814263,66678,50587,856
31 Mar 17758,701215,81265,77887,856
31 Dec 16670,581158,95875,51787,856
30 Sep 16630,045176,69996,72237,320
30 Jun 16631,225181,01588,83537,320
31 Mar 16614,243179,60584,30637,320
31 Dec 15603,413154,09066,69637,320
30 Sep 15534,991117,38944,62069,642
30 Jun 15470,68270,14452,55169,642
31 Mar 15481,79784,08366,04069,642
31 Dec 14471,046112,67664,76769,642
30 Sep 14373,93697,60482,92825,386
30 Jun 14349,650118,98762,67825,386
31 Mar 14232,29283,00739,32117,804
31 Dec 13226,208102,45525,24125,386

Quality Earnings: A068270 has high quality earnings.

Growing Profit Margin: A068270's current net profit margins (6.5%) are lower than last year (26.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A068270's earnings have grown by 1.6% per year over the past 5 years.

Accelerating Growth: A068270's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A068270 had negative earnings growth (-69%) over the past year, making it difficult to compare to the Biotechs industry average (7.9%).


Return on Equity

High ROE: A068270's Return on Equity (1.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies